TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2667525

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg/dihydroergotoxin 2 mg
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 409028

Group type: EXPERIMENTAL
Intervention: Progestogen-only oral contraceptives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined progestogen-oestrogen oral contraceptives
Number of subjects: 0
Study: 31838367

Group type: EXPERIMENTAL
Intervention: Social support satisfaction
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Self-perceived competence in the ability to withdraw
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Benzodiazepine intake factors (length of use and dose)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Psychological factors
Number of subjects: 73
Study: 30874724

Group type: EXPERIMENTAL
Intervention: Triple therapy (OAC plus aspirin and clopidogrel) for 4 weeks, followed by dual therapy (N)OAC plus clopidogrel until 12 months post-PCI, then (N)OAC monotherapy indefinitely.
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Use of lower dose of NOAC in combination with antiplatelet(s) as per current recommendations.
Number of subjects: 47
Study: 28129215

Group type: EXPERIMENTAL
Intervention: Classic inverted ILM flap technique (Group 1)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Modified procedure with no extra flap manipulation (Group 2)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Modified inverted ILM technique
Number of subjects: 81
Study: 25586810

Group type: EXPERIMENTAL
Intervention: Telemonitoring
Number of subjects: 256

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 256
Study: 23782557

Group type: EXPERIMENTAL
Intervention: Low-cost, supportive footwear (Dr Comfort®, Vasyli Medical) in addition to usual DVA-subsidized podiatry care
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual DVA-subsidized podiatry care without the footwear
Number of subjects: 120
Study: 21385975

Group type: EXPERIMENTAL
Intervention: Airway Scope in left-lateral position
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Airway Scope in right-lateral position
Number of subjects: 129

Group type: COMPARATOR
Intervention: Airway Scope in supine position
Number of subjects: 129
Study: 17600848

Group type: EXPERIMENTAL
Intervention: Folic acid (1 mg)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 16139810

Group type: EXPERIMENTAL
Intervention: Schizophrenia patients
Number of subjects: 52
Study: 12658428

Group type: EXPERIMENTAL
Intervention: Laparoscopic total extraperitoneal (TEP) repair
Number of subjects: 50

Group type: COMPARATOR
Intervention: Open tension-free mesh Lichtenstein repair
Number of subjects: 50
Study: 10842262

Group type: EXPERIMENTAL
Intervention: Linear estimates of disease progression (LEP) based on grip or foot dorsiflexion (FD) strength and forced vital capacity (FVC%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LEP based on FD strength
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LEP based on FVC%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LEP based on all measures
Number of subjects: 0
Study: 8888417

Group type: EXPERIMENTAL
Intervention: Preperformance behaviors (rituals) during golf putt, basketball free throw, and tennis serve.
Number of subjects: 7
Study: 6359570

Group type: EXPERIMENTAL
Intervention: Urokinase 2,200 I.U./kg/hr
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Urokinase 1,100 I.U./kg/hr
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Streptokinase initial dose of 250,000 I.U. followed by 100,000 I.U./hr
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Urokinase (both dosages)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Urokinase treated patients
Number of subjects: 33
Study: 30205667

Group type: EXPERIMENTAL
Intervention: Lung ultrasonography (LUS)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Auscultation
Number of subjects: 91
Study: 29336133

Group type: EXPERIMENTAL
Intervention: Multi-colour sound generators (white, red, pink noise)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional white noise sound generators
Number of subjects: 20
Study: 27609525

Group type: EXPERIMENTAL
Intervention: Focal psychodynamic therapy (FPT)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Enhanced cognitive-behavioural therapy (CBT-E)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Treatment as usual (TAU-O)
Number of subjects: 156
Study: 25056510

Group type: EXPERIMENTAL
Intervention: Low-dose hydrocortisone therapy (steroid group)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Control group (no hydrocortisone)
Number of subjects: 259
Study: 21955475

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control
Number of subjects: 105
Study: 19670560

Group type: EXPERIMENTAL
Intervention: Lateral decubitus position (LSP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Supine position (SP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Comparison of LSP and SP
Number of subjects: 10
Study: 17441877

Group type: EXPERIMENTAL
Intervention: Herculite XRV direct composite restorations
Number of subjects: 18
Study: 15247722

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 12198615

Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 2418
Study: 11705307

Group type: EXPERIMENTAL
Intervention: Alitretinoin gel 0.1%
Number of subjects: 134

Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 134
Study: 9440643

Group type: EXPERIMENTAL
Intervention: Fructose (25 g)
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Sorbitol (5 g)
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Lactulose (10 g)
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Glucose (50 g)
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Lactose (25 g)
Number of subjects: 520
Study: 8273381

Group type: EXPERIMENTAL
Intervention: General anesthesia combined with epidural bupivacaine (group 2)
Number of subjects: 10

Group type: COMPARATOR
Intervention: General anesthesia only (group 1)
Number of subjects: 10
Study: 3687262

Group type: EXPERIMENTAL
Intervention: Roux stomach replacement method
Number of subjects: 27

Group type: COMPARATOR
Intervention: Longmire stomach replacement method
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Body weight and general condition
Number of subjects: 27
Study: 29432650

Group type: EXPERIMENTAL
Intervention: Ultrasonic removal of fractured files from the middle third of root canals followed by instrumentation with the ProTaper Next (PTN) system.
Number of subjects: 18

Group type: COMPARATOR
Intervention: ProTaper Next (PTN) system instrumentation only (control group).
Number of subjects: 18
Study: 28164639

Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Intravenous dexketoprofen
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Intravenous tramadol
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 77
Study: 24372612

Group type: EXPERIMENTAL
Intervention: Neopterin-to-creatinine ratio
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Upper quartiles of neopterin-to-creatinine ratio
Number of subjects: 0
Study: 23271697

Group type: EXPERIMENTAL
Intervention: Seated with 2-min bouts of light- or moderate-intensity treadmill walking every 20 min
Number of subjects: 8

Group type: COMPARATOR
Intervention: Seated position with no activity
Number of subjects: 8
Study: 20004371

Group type: COMPARATOR
Intervention: Diet only
Number of subjects: 104

Group type: COMPARATOR
Intervention: Diet and aerobic exercise
Number of subjects: 104

Group type: COMPARATOR
Intervention: Diet and combined aerobic-resistance exercise
Number of subjects: 104
Study: 17712634

Group type: EXPERIMENTAL
Intervention: E. coli strain Nissle 1917 (EcN)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 16113846

Group type: EXPERIMENTAL
Intervention: Surgical myocardial revascularization (SMR)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Coronary angioplasty (TCA)
Number of subjects: 96
Study: 12515745

Group type: EXPERIMENTAL
Intervention: Effective nCPAP treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Subtherapeutic nCPAP
Number of subjects: 60
Study: 10500312

Group type: EXPERIMENTAL
Intervention: Urokinase (UK) high-dose group (18,000 IU/kg, max 1.5 million IU)
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Urokinase (UK) low-dose group (14,000 IU/kg, max 1 million IU)
Number of subjects: 556

Group type: COMPARATOR
Intervention: Control group (heparin)
Number of subjects: 556
Study: 8880557

Group type: EXPERIMENTAL
Intervention: Combination preparation (Diltiazem 150 mg / Hydrochlorothiazide 12.5 mg)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Diltiazem (150 mg)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (12.5 mg)
Number of subjects: 71
Study: 1995100

Group type: EXPERIMENTAL
Intervention: Very Fresh Whole Blood (VFWB)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: 24- to 48-hour-old Whole Blood
Number of subjects: 161

Group type: COMPARATOR
Intervention: Reconstituted Whole Blood (packed red blood cells, FFP, and platelets)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Reconstituted Whole Blood
Number of subjects: 161
Study: 30460353

Group type: EXPERIMENTAL
Intervention: 67% NaHCO3 toothpaste
Number of subjects: 247

Group type: COMPARATOR
Intervention: 0% NaHCO3 toothpaste
Number of subjects: 247
Study: 27038114

Group type: EXPERIMENTAL
Intervention: Alpha neurofeedback training (NFT) with 8‐12‐Hz amplitude
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group receiving random 4‐Hz amplitude
Number of subjects: 50
Study: 24374502

Group type: EXPERIMENTAL
Intervention: ORV-116E vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher dose of ORV-116E vaccine
Number of subjects: 0
Study: 22842994

Group type: EXPERIMENTAL
Intervention: Continuous ART (cART) for 72 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: cART for 36 weeks followed by three ART-STIs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ART-STIs associated with pegylated interferon alpha-2b (peg-IFN) during the first 14 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: All regimens (cART, ART-STI, ART-STI-IFN)
Number of subjects: 0
Study: 20542512

Group type: EXPERIMENTAL
Intervention: n‐3 PUFA ethyl ester capsules
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control capsules
Number of subjects: 121
Study: 19025504

Group type: EXPERIMENTAL
Intervention: Early physiotherapy intervention (education, reassurance, pain management, mobility training, interferential therapy, walking training, and walking aids)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (only walking training and walking aids)
Number of subjects: 110
Study: 16271485

Group type: EXPERIMENTAL
Intervention: Subtalar strapped insole (n=21)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Traditional shoe inserted wedged insole (n=21)
Number of subjects: 42
Study: 14767409

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g/day for 1 week, then 3 g/day for 2 weeks)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 26
Study: 11235060

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 9286467

Group type: EXPERIMENTAL
Intervention: Three meals per day
Number of subjects: 10

Group type: COMPARATOR
Intervention: Eight meals per day
Number of subjects: 10
Study: 8416077

Group type: EXPERIMENTAL
Intervention: Stimulus presentation rate at 1.3 s ISI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimulus presentation rate at 2.1 s ISI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimulus presentation rate at 2.9 s ISI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fast and accurate choice responses to tones
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lateralized readiness potential
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: P300 latency
Number of subjects: 0
Study: 3516431

Group type: EXPERIMENTAL
Intervention: Combination of cyclophosphamide (600 mg/m2), methotrexate (40 mg/m2), 5‐fluorouracil (600 mg/m2) IV every 3 weeks and prednisone 20 mg/m2 PO daily, with diminishing doses (intermittent group)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination of cyclophosphamide (100 mg/m2 PO on days 1‐15, alternating with a 15‐day rest period), methotrexate 20 mg/m2 IV, 5‐fluorouracil 500 mg/m2 IV weekly for 20 weeks and prednisone 20 mg/m2 PO daily, with diminishing doses in the remission induction period, followed by a maintenance regimen (intensive group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intensive group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intermittent group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 100
Study: 31432535

Group type: EXPERIMENTAL
Intervention: Cooperative learning
Number of subjects: 1890
Study: 30141230

Group type: EXPERIMENTAL
Intervention: Proton therapy with uniform scanning or pencil beam scanning, prescribed doses of 50.4‐66.4 Gy(RBE) scaled to 50.4 Gy(RBE) for analysis.
Number of subjects: 52
Study: 27185621

Group type: EXPERIMENTAL
Intervention: Guy2Guy, a text messaging–based HIV prevention/healthy sexuality program
Number of subjects: 302
Study: 25412862

Group type: EXPERIMENTAL
Intervention: Intervention group (EdAl-2 programme)
Number of subjects: 690

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 690
Study: 22963354

Group type: EXPERIMENTAL
Intervention: Computer-tailored printed advice targeting health behaviours
Number of subjects: 2306

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2306
Study: 20489580

Group type: COMPARATOR
Intervention: Cefazolin (5%) and Tobramycin (1.3%)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Gatifloxacin (0.3%)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (0.5%)
Number of subjects: 61
Study: 18560218

Group type: EXPERIMENTAL
Intervention: rtPA thrombolysis
Number of subjects: 16

Group type: COMPARATOR
Intervention: minor stroke (not receiving rtPA)
Number of subjects: 16
Study: 15836828

Group type: EXPERIMENTAL
Intervention: Ulinastatin treatment (100 kU intravenously drip, once every 8 hours for 5 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ulinastatin treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ulinastatin treatment and Routine treatment
Number of subjects: 60
Study: 11979417

Group type: EXPERIMENTAL
Intervention: Extended lymphadenectomy (ELND)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine extended lymphadenectomy (ELND)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical resection
Number of subjects: 0
Study: 10084094

Group type: EXPERIMENTAL
Intervention: Direct laryngeal/tracheal lignocaine spray immediately before intubation (Group A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Orolaryngeal lignocaine spray before induction of anaesthesia (Group B)
Number of subjects: 30
Study: 7669712

Group type: EXPERIMENTAL
Intervention: IFN + VMCP
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: IFN maintenance
Number of subjects: 256

Group type: COMPARATOR
Intervention: VMCP
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Global evaluations
Number of subjects: 256
Study: 1974675

Group type: EXPERIMENTAL
Intervention: Tulobuterol 2 mg tablets taken twice daily for 12 weeks
Number of subjects: 140

Group type: COMPARATOR
Intervention: Salbutamol 4 mg tablets taken three times daily for 12 weeks
Number of subjects: 140
Study: 6769930

Group type: EXPERIMENTAL
Intervention: Noxythiolin for peritoneal toilet during operation
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study: 30902087

Group type: EXPERIMENTAL
Intervention: Procedural sedation and analgesia with propofol in an outpatient setting
Number of subjects: 205

Group type: COMPARATOR
Intervention: General anaesthesia in a clinical setting in the operating theatre
Number of subjects: 205
Study: 28448234

Group type: EXPERIMENTAL
Intervention: SPM
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: FSL
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: FreeSurfer
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: SPM's voxel-based morphometry
Number of subjects: 38
Study: 25454736

Group type: EXPERIMENTAL
Intervention: Transcatheter arterial embolization (TAE) using N-butyl cyanoacrylate (NBCA)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Transcatheter arterial embolization (TAE) using gelatin sponge particles
Number of subjects: 26
Study: 22236044

Group type: EXPERIMENTAL
Intervention: Bio‐Oss® (group 1)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Straumann BoneCeramic® (group 2)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no dehiscence)
Number of subjects: 14
Study: 21743091

Group type: EXPERIMENTAL
Intervention: Inpatient falls prevention education
Number of subjects: 343

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Receiving assistance with activities of daily living
Number of subjects: 343
Study: 18955509

Group type: EXPERIMENTAL
Intervention: Interobserver agreement in rating disk degeneration
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Interobserver agreement in rating spondylolisthesis
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Interobserver agreement in rating Modic changes
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Interobserver agreement in rating facet arthropathy
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Interobserver agreement in rating posterior HIZ
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Intraobserver agreement in rating spondylolisthesis
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Intraobserver agreement in rating disk degeneration
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Intraobserver agreement in rating Modic changes
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Intraobserver agreement in rating facet arthropathy
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Intraobserver agreement in rating posterior HIZ
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Intraobserver agreement in rating extent of Modic changes (superior anteroposterior)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Intraobserver agreement in rating extent of Modic changes (inferior anteroposterior)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Intraobserver agreement in rating extent of Modic changes (superior craniocaudal)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Intraobserver agreement in rating extent of Modic changes (inferior craniocaudal)
Number of subjects: 111
Study: 17079828

Group type: EXPERIMENTAL
Intervention: Stimulation therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: No stimulation (Control)
Number of subjects: 60
Study: 12829943

Group type: EXPERIMENTAL
Intervention: Interventions conducted through an academic-community partnership
Number of subjects: 0
Study: 10993998

Group type: EXPERIMENTAL
Intervention: Low-dose olanzapine (2.5 to 7.5 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8792694

Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1401644

Group type: EXPERIMENTAL
Intervention: Cooked lyophilized fish extracts
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Canned tuna
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Canned salmon
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Canned fish extracts
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Canned tuna and salmon
Number of subjects: 45
Study: 2864944

Group type: EXPERIMENTAL
Intervention: Single bolus dose of vecuronium (10-50 micrograms kg-1)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Cumulative dose technique
Number of subjects: 28
Study: 30143885

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 1800 mg/day
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no EPA)
Number of subjects: 100
Study: 29367439

Group type: EXPERIMENTAL
Intervention: Arimoclomol 200 mg tid
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 27928077

Group type: EXPERIMENTAL
Intervention: Empiric four-drug anti-TB treatment followed 2 weeks later by efavirenz-based ART (ART + TB)
Number of subjects: 43

Group type: COMPARATOR
Intervention: ART only
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both groups (ART + TB and ART only)
Number of subjects: 43
Study: 25230038

Group type: EXPERIMENTAL
Intervention: Traditional assessment with the presence of an evaluator
Number of subjects: 20

Group type: COMPARATOR
Intervention: Filmed assessment without the presence of an evaluator
Number of subjects: 20
Study: 22781526

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.25 µg × kg(‐1)× h(‐1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 µg × kg(‐1)× h(‐1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.75 µg × kg(‐1)× h(‐1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.0 µg × kg(‐1)× h(‐1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dexmedetomidine (all doses) vs Control
Number of subjects: 100
Study: 20234330

Group type: EXPERIMENTAL
Intervention: 2-week antibiotic treatment regimen
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: 3-week antibiotic treatment regimen
Number of subjects: 218

Group type: COMPARATOR
Intervention: APN (control group)
Number of subjects: 218
Study: 19090296

Group type: EXPERIMENTAL
Intervention: Lymphocyte Proliferation (LP)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Viral Neutralization Test (VNT)
Number of subjects: 100